达泊西汀（INN, 商品名Priligy），一种新型快速的SSRI，半衰期短，属于选择性5-羟色胺再吸收抑制剂(SSRI)，是一款用于治疗16至84周岁男性早泄的药物。达泊西汀最早由美国礼来公司开发，后在2003年被售予美国强生公司，并于2004年作为治疗早发性射精的药物被提交给美国食品药品监督管理局进行批准。在美国，从2003年起达泊西汀就一直处于III期临床试验阶段，但一般认为它将会很快上市。2012年，意大利美纳里尼公司获取了达泊西汀的商业权利，包括在欧洲、大部分的亚洲、非洲、拉丁美洲以及中东进行销售的权利。目前仍未获得美国食品药物管理局批准，但已通过了中国、芬兰、瑞典、葡萄牙、奥地利、意大利、西班牙等国的审批。

Dapoxetine, marketed as Priligy and Westoxetin, among and other brands, is the first compound developed specially for the treatment of premature ejaculation (PE) in men 18–64 years old. Dapoxetine works by inhibiting the serotonin transporter, increasing serotonin's action at the post synaptic cleft, and as a consequence promoting ejaculatory delay. As a member of selective serotonin reuptake inhibitor (SSRI) family, dapoxetine was initially created as an antidepressant. However, unlike other SSRIs, dapoxetine is absorbed and eliminated rapidly in the body. Its fast acting property makes it suitable for the treatment of PE but not as an antidepressant.